Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Opioid

or [[:Category:Basal_insulins|Basal insulin]]

Use the filters below to narrow your results.

Codeine (2)

None (12)

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Sodium channel blocker (2)

Other values:

None (48) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) · '"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"' (1) · '"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1)

None (48) · Adult: 15–60 mg every 4 hours as needed. (1) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)

None (48) · 100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) · 100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) · 100 U/mL FlexTouch pen, vial (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (48) · 360 mg/day (1) · Titrated to glucose (1) · Titrated to glucose; no fixed ceiling (2)

None (48) · PO (only formulation marketed in the US). (1) · Subcutaneous (1) · Subcutaneous (never IV; not for use in insulin pumps) (2)

None (48) · 1-2 hours (2) · 30–60 min (PO) (1) · ~1 hour (1)

None (48) · 4–6 hours (1) · >42 hours per dose (effectively flat once at steady state) (1) · ~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1) · ~24 hours per dose (peakless profile by design) (1)

None (48) · 2.5–3 hours (1) · ~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) · ~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1) · ~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1)

None (48) · ~100% from subcutaneous depot (1) · ~100% from subcutaneous depot (by definition of the route) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)

None (48) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (48) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (3)

Showing below up to 52 results in range #1 to #52.

7

7-Hydroxymitragynine

A

B

C

D

E

F

Felbamate

H

I

K

Kratom

L

M

N

Nalbuphine

O

P

R

S

T

U

U-47700

V

Z

Zonisamide

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"